WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials. The QUANTI studies examined gadoquatrane at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback